US Patent Issued to CONDUIT UK MANAGEMENT on Aug. 5 for "Therapeutic cocrystals of 3-{[5-(azetidine-1-ylcarbonyl)pyrazin-2-yloxy}-5-{[(1S)-1-methyl-2-(methyloxy)ethyloxy)-N-(5-methylpyrazin-2-yl)benzamide" (British Inventors)

ALEXANDRIA, Va., Aug. 6 -- United States Patent no. 12,378,227, issued on Aug. 5, was assigned to CONDUIT UK MANAGEMENT LTD (London).

"Therapeutic cocrystals of 3-{[5-(azetidine-1-ylcarbonyl)pyrazin-2-yloxy}-5-{[(1S)-1-methyl-2-(methyloxy)ethyloxy)-N-(5-methylpyrazin-2-yl)benzamide" was invented by Alex Eberlin (Cambridge, Great Britain), Christopher Frampton (Suffolk, Great Britain) and Joanne Holland (Cambridgeshire, Great Britain).

According to the abstract* released by the U.S. Patent & Trademark Office: "Cocrystals of a benzamide compound, specifically 3-{[5-(azetidine-1-ylcarbonyl)pyrazin-2-yl]oxy}-5-{[(1S)-1-methyl-2-(methyloxy)ethyl]oxy}-N-(5-methylpyrazin-2-yl)benzamide, therapeutic uses of the benzamide cocrystals and pharmaceut...